Ultragenyx Pharmaceutical Rebound Potential

16 days ago

Nora Melinda

"Yes, this is ticker rare R A R E. We're seeing shares up about 13% right now. This is a company on the smaller side, about $96 million in market cap, but we are seeing shares up for double-digit gains. This is the biggest jump we've seen since August of 2024 for the stock. This is a rebound after, yes, or back in Monday. Yesterday we saw that shares hit a record low on a study failure. Jeffrey's analysts are talking about the fact that the stock could rebound into next year ahead of a late stage data update. So, we'll keep our eyes all over this biotech company, but not doing too hot this year either. Shares are down about 47% so far."

The discussion on Ultragenyx Pharmaceutical (RARE) centers on a significant 13% rebound following a record low due to a study failure, with commentary suggesting potential recovery into next year despite a 47% decline year-to-date.

Related Stocks